Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK
- PMID: 21432940
- DOI: 10.1002/gcc.20868
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK
Abstract
Approximately 25,000 ovarian cancers are diagnosed in the United States annually, and 75% of cases are in the advanced stage when they are largely incurable. There is a critical need for improved early detection tools and development of novel treatments. Recently, we showed that among 20q13-amplified genes in ovarian cancer, ADRM1 overexpression was the most highly correlated with amplification and was significantly upregulated with respect to stage, recurrence, and metastasis. In addition, overexpression of ADRM1 correlated significantly with shorter time to recurrence and overall survival. Herein, array-CGH and microarray expression of ovarian cancer cell lines provides evidence consistent with the primary tumor data that ADRM1 is a 20q13 amplification target. Knockdown of ADRM1 in amplified ovarian cell-line OAW42 results in downregulation of growth factor GIPC1 and upregulation of tumor-suppressor RECK RNA and protein. In our dataset of 141 ovarian primary tumors, ADRM1 overexpression significantly correlates with GIPC1 overexpression. In addition, there is a significant anticorrelation between ADRM1 overexpression and RECK expression. Further research is necessary to determine whether targeting knockdown of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK.
Copyright © 2011 Wiley-Liss, Inc.
Similar articles
-
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.Int J Mol Sci. 2013 Feb 1;14(2):3094-109. doi: 10.3390/ijms14023094. Int J Mol Sci. 2013. PMID: 23377018 Free PMC article.
-
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.Genes Chromosomes Cancer. 2008 Oct;47(10):873-83. doi: 10.1002/gcc.20592. Genes Chromosomes Cancer. 2008. PMID: 18615678
-
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.Cancer. 2010 Jun 1;116(11):2621-34. doi: 10.1002/cncr.24987. Cancer. 2010. PMID: 20336784
-
Functional proteomics, human genetics and cancer biology of GIPC family members.Exp Mol Med. 2013 Jun 7;45(6):e26. doi: 10.1038/emm.2013.49. Exp Mol Med. 2013. PMID: 23743496 Free PMC article. Review.
-
What we learn from transformation suppressor genes: lessons from RECK.Future Oncol. 2010 Jul;6(7):1105-16. doi: 10.2217/fon.10.80. Future Oncol. 2010. PMID: 20624123 Review.
Cited by
-
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.PLoS One. 2021 Sep 10;16(9):e0256937. doi: 10.1371/journal.pone.0256937. eCollection 2021. PLoS One. 2021. PMID: 34506530 Free PMC article.
-
Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11.Cell Chem Biol. 2020 Nov 19;27(11):1383-1395.e5. doi: 10.1016/j.chembiol.2020.08.008. Epub 2020 Aug 27. Cell Chem Biol. 2020. PMID: 32857986 Free PMC article.
-
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.Int J Mol Sci. 2013 Feb 1;14(2):3094-109. doi: 10.3390/ijms14023094. Int J Mol Sci. 2013. PMID: 23377018 Free PMC article.
-
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.ACS Omega. 2018 Sep 30;3(9):11917-11929. doi: 10.1021/acsomega.8b01479. Epub 2018 Sep 27. ACS Omega. 2018. PMID: 30288466 Free PMC article.
-
HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis.PLoS One. 2012;7(3):e33585. doi: 10.1371/journal.pone.0033585. Epub 2012 Mar 16. PLoS One. 2012. PMID: 22438955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases